Intelligent Bio Solutions Inc. (INBS)
NASDAQ: INBS · Real-Time Price · USD
1.400
+0.020 (1.45%)
At close: Nov 20, 2024, 4:00 PM
1.440
+0.040 (2.86%)
Pre-market: Nov 21, 2024, 7:29 AM EST

Company Description

Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions.

The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse.

It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.

The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.

Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York. The company operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Intelligent Bio Solutions Inc.
Intelligent Bio Solutions logo
Country United States
Founded 2016
Industry Medical Devices
Sector Healthcare
Employees 50
CEO Harry Simeonidis

Contact Details

Address:
135 West, 41ST Street, 5th Floor
New York, New York 10036
United States
Phone 646 828 8258
Website ibs.inc

Stock Details

Ticker Symbol INBS
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001725430
ISIN Number US36151G6008
Employer ID 82-1512711
SIC Code 3841

Key Executives

Name Position
Harry Simeonidis President and Chief Executive Officer
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law Chief Financial Officer
Alex Arzeno Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Nov 20, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 8-K Current Report
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Sep 27, 2024 8-K Current Report
Sep 27, 2024 8-K Current Report
Sep 19, 2024 8-K Current Report